2023 was a tricky calendar year with the biopharma sector, with a number of corporations downsizing and restructuring their workforces to stay afloat. You will find indications of Restoration, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences sector while in the latter Component of 2023 https://sites.google.com/view/bio-sites/blog